Affimed Names Shawn M. Leland New CEO to Drive Growth
Affimed Appoints Shawn M. Leland as Chief Executive Officer
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company dedicated to empowering patients in their fight against cancer, has recently announced the appointment of Shawn M. Leland, PharmD, RPh as its new Chief Executive Officer (CEO). This strategic move comes as the company focuses on advancing its innovative pipeline of cancer therapies. Dr. Andreas Harstrick will continue to serve as Chief Medical Officer (CMO) after his tenure as acting CEO.
Leadership Experience and Background
Shawn Leland brings over 15 years of extensive experience in the pharmaceutical and biotechnology sectors. His solid track record includes successfully driving the development of novel oncology therapies, securing significant funding for biotech firms, and establishing essential strategic partnerships. His leadership prowess is expected to play a crucial role in steering Affimed’s growth trajectory and corporate strategy.
Recent Achievements
Before joining Affimed, Shawn served as the Interim CEO and Board Director of ForeBio, where he led the company through a successful phase 2 study and oversees a notable $75 million Series D financing round. Additionally, he founded Elevation Oncology in July 2019, where he initially acted as Chief Business Officer before stepping into the role of CEO until January 2023. His efforts during this period resulted in the advancement of targeted oncology therapeutics and raising over $200 million, highlighted by a $100 million IPO.
Previous Roles in Industry
From 2017 to 2019, Shawn was at the helm of Business Development at Verastem Oncology and had a similar role at Argos Therapeutics from 2013 to 2017. His impactful contributions in these roles significantly shaped both companies' corporate development frameworks, facilitating numerous partnerships and licensing agreements. Shawn commenced his career at ARIAD Pharmaceuticals and Eli Lilly, where he gained invaluable industry insights.
Vision for Affimed’s Future
Expressing his enthusiasm for his new role, Shawn stated, “Affimed possesses a robust pipeline with three clinical-stage assets, all demonstrating clinical proof of concept. This validates our mission to leverage the innate immune system in cancer treatment.” He emphasized his readiness to lead the company towards key milestones, ensuring that innovative therapies are delivered to patients in need while maximizing shareholder value.
Insights from the Supervisory Board
Dr. Thomas Hecht, Chairman of Affimed’s Supervisory Board, shared, “We are thrilled to welcome Shawn as our new CEO. His history of leadership and entrepreneurial spirit in the biotech sector, especially in challenging environments, gives us confidence in his vision for Affimed’s future.” He acknowledged Dr. Harstrick's valuable contributions during his interim leadership, guiding the company into a focused clinical development phase.
Conclusion
With Shawn M. Leland at the helm, Affimed is poised to advance its innovative objectives in immuno-oncology. The company looks forward to achieving critical clinical milestones and expanding its therapeutic reach to benefit patients while enhancing shareholder value.
Frequently Asked Questions
Who is the new CEO of Affimed?
Shawn M. Leland has been appointed as the new CEO of Affimed N.V.
What previous experience does Shawn Leland have?
Shawn has over 15 years of experience in biotechnology, previously serving as Interim CEO of ForeBio and founding Elevation Oncology.
What does Affimed specialize in?
Affimed specializes in immuno-oncology, aiming to harness the innate immune system to develop therapies for cancer treatment.
What is the significance of Shawn's appointment?
His appointment signals a strong commitment to advancing Affimed’s clinical programs and maximizing growth potential in a competitive market.
How has Affimed positioned itself in the oncology sector?
Affimed has developed a robust pipeline with three clinical-stage assets, demonstrating strong potential and validating its strategic approach.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Lerner Publishing Group Expands Portfolio with New Acquisition
- Plastic Caps and Closures Market Set to Reach USD 96.28 Billion
- Global PET-CT Scanner Market Set for $4.9 Billion Growth
- DemandScience Achieves a Historic 11th Inc. 5000 Honor
- Object Management Group Launches New Journal of Innovation
- Healthcare Mobility Solutions Market Foresees Major Growth
- Sustainable Apparel Market Projected to Hit USD 24.53 Billion
- Bio-Based Coatings Market Growth Driven by Eco-Friendly Demand
- Fleet Management Software Market Growth to USD 93.17 Billion
- Optical Modulators Market Growth Metrics and Key Drivers
- The Surging Mixed Reality Market: Predicted to Hit USD 76.91 Billion
- ChartPath and WoundZoom Partner to Revolutionize Wound Care
- IR Spectroscopy Market Growth Predictions Highlighted by R&D
- Global Cash Handling Device Market Growth Insights
- Nutricosmetics Market Expected to Exceed $16.93 Billion Growth
- Ignitis Group Commits to 174 MW Tume Solar Project
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- GeoVax Labs, Inc. Announces Upcoming Investor Events!
- John Ballantyne Joins Glucotrack Board to Advance Innovation
- Fortun Advance Reports Rapid Asset Growth and Appoints New VP
- Equip Exposition Appoints Chris Meecha as New Show Director
- Bango Partners with Disney+ to Expand Subscriber Offerings
- Semnur Pharmaceuticals and Denali Capital to Merge for Growth
- ThreatHunter.ai Launches Free Cybersecurity Tool for Businesses
- Treasure Global Inc Appoints New Directors to Enhance Growth
Recent Articles
- BW Offshore Adjusts Convertible Bonds for Shareholders' Dividend
- Procaps Group Outlines Strategic Vision for Future Success
- Object Management Group Launches New Journal of Innovation
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- Strider Bikes Hosts an Exciting Adventure-Cross Race
- Sacks Parente Golf to Shine at H.C. Wainwright Conference
- Pasithea Therapeutics Welcomes Dr. Rebecca Brown to Advisory Board
- Kohl's vs. Visa: A Deep Dive into Dividends and Growth Potential
- EmergeOrtho-Triangle Region Welcomes Dr. Kyle E. Nappo, M.D.
- Natural Grocers® Partners with Rodale Institute for Organic Growth
- Vaxcyte's VAX-31 Vaccine Shows Promising Phase 1/2 Study Results
- TransUnion CEO to Speak at Barclays Global Financial Conference
- Evolution Space Celebrates Successful Sea Launch of Hypersonic Rocket
- W&T Offshore Welcomes New General Counsel George Hittner
- Chris Ramirez Joins mesur.io as New VP of Sales to Drive Growth
- NANO Nuclear Energy Inc. Class Action Lawsuit Update for Investors
- MacroGenics, Inc. Investors Encouraged to Contact Legal Team
- Global Toys Market Predicted to Hit $530.04 Billion by 2033
- Michael Saylor's Bold Bitcoin Predictions and ETF Insights
- AEG Launches Innovative Kitchen Range Featuring AI Cooking
- European Markets Rise Cautiously; Investors Analyze Data Trends
- Market Insights for September: Economic Trends to Watch
- Orexo's Upcoming Participation in Annual Healthcare Conference
- Boehringer Ingelheim Acquires Saiba Animal Health for Pet Care
- Siili Solutions Plc: Recent Holdings Notification Update